This article summarizes the most significant insider buys and sells reported for Wednesday, April 2, 2025, in US stocks.

Top Insider Buys:

American Strategic Investment Co. (NYSE: NYC ) saw substantial insider purchases by key stakeholders. Nicholas S. Schorsch, through entities like Bellevue Capital Partners, LLC and AR Global Investments, LLC, acquired Class A common stock worth approximately $49,736. The shares were bought at prices ranging from $11.56 to $12.16, near the current price of $11.27. This acquisition increased Schorsch’s total ownership to 979,701 shares. Despite the stock’s impressive 81% return over the past year, the company operates with significant debt and has not been profitable in the last twelve months.

Staar Surgical Co. (NASDAQ: STAA ) experienced notable insider buying from Broadwood Partners, L.P., a significant shareholder. The firm acquired shares totaling approximately $941,285, despite the stock’s nearly 50% decline over the past six months. The purchases were executed on March 31 and April 2, involving 22,189 shares at an average price of $17.46 and 31,780 shares at $17.43 per share. Staar Surgical maintains a strong balance sheet with more cash than debt, according to InvestingPro data.

JELD-WEN Holding, Inc. (NYSE: JELD ) saw Turtle Creek Asset Management Inc. significantly increase its stake by purchasing 108,240 shares of common stock. The transactions, occurring on March 31 and April 1, were executed at prices ranging from $5.87 to $6.00 per share, totaling $742,112. This move comes as JELD-WEN’s stock has experienced significant volatility, down over 70% in the past year and trading near its 52-week low of $5.44. Despite the company’s current debt burden, its liquid assets exceed short-term obligations.

Zymeworks Inc . (NASDAQ: ZYME ) witnessed substantial insider activity involving EcoR1 Capital, LLC, and director Oleg Nodelman. The transactions, spanning March 31 to April 2, involved the acquisition of 127,415 shares of common stock at prices ranging from $11.6044 to $11.848 per share, totaling approximately $1.5 million. This continued interest from EcoR1 Capital and Nodelman reflects their confidence in the pharmaceutical company.

First Guaranty Bancshares Inc . (NASDAQ: FGBI ) director William K. Hood expanded his holdings by purchasing 98,460 shares at $8.47 per share, totaling $833,956. This transaction occurred amid a significant stock decline of nearly 27% over the past six months. Hood now holds 98,460 shares directly through WK Hood Family, LLC, with additional indirect ownership in several other entities.

Top Insider Sells:

CoreWeave , Inc. (NASDAQ: CRWV ) reported significant sales by Chief Strategy Officer Brian M. Venturo, CEO Michael Intrator, and director Jack D. Cogen. Venturo and related entities sold 1,597,000 shares at $47 per share, totaling $74.97 million. Intrator sold 1,064,940 shares at $47 each, amounting to approximately $50 million. Cogen disposed of shares valued at approximately $62.67 million. These sales occurred as CoreWeave’s stock trades near its 52-week high, with a market capitalization of $24.4 billion.

Corcept Therapeutics Inc. (NASDAQ: CORT ) saw substantial insider selling from Sean Maduck, President of Corcept Endocrinology, and Joseph Douglas Lyon, Chief Accounting & Technology Officer. Maduck sold 100,000 shares for approximately $10.1 million, while Lyon sold 200,650 shares for about $20.2 million. Both executives also exercised options to acquire shares. These transactions occurred as Corcept’s stock surged 226% over the past year, with the company now valued at $8.86 billion.

Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company’s prospects. While insider transactions alone should not be the sole basis for investment decisions, they can offer clues about management’s confidence in the company’s future performance and potential market trends.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.